Dr Clive B. Archer’s publications
Lacy K, Karagiannis S and Nestle F (ed. Archer CB). Advances in the treatment of melanoma. Clin Med 2012
Apr;12 (2):168-71.
Baron SE, Cohen SN and Archer CB. Guidance on the diagnosis and clinical management of atopic eczema. (on
behalf of the BAD and RCGP), Clin Exp Dermatol 2012; May;37 Suppl 1:7-12. doi: 10.1111/j.13652230.2012.04336.x.
Archer CB. Immunopharmacological mechanisms in atopic dermatitis. In: Harper J, Oranje A, Prose N. eds:
Textbook of Paediatric Dermatology, 3rd edition, Wiley - Blackwell (Oxford) 2011; 25.1-25.13.
Lacy K, Archer C, Wood K and Bidwell J. Association between a common IL10 distal promoter haplotype and
IgE production in individuals with atopic dermatitis. Int J Immungenetics 2009; 36: 213-16.
Archer CB. Ethnic Dermatology: Clinical Problems and Skin Pigmentation. Publisher: Informa Healthcare, 2008;
pp 1-198.
Finucane KA, Archer CB. Recent advances in nephrology: Calcific uraemic arteriolopathy; nephrogenic fibrosing
dermopathy; management of uraemic pruritus; skin cancers after renal transplantation. Clin Exp Dermatol
2005; 30: 98–102.
Gompels MM, Lock RJ, Unsworth DJ, Johnson SL, Archer CB, Davies SV. Misdiagnosis of hereditary angioedema
type 1 and type 2. Br J Dermatol 2003; 148: 719-723.
Jenks PJ, Kavanagh GM, Brooks J, Bradfield JWB, Archer CB. Comparison of weal and flare responses to platelet
activating factor (PAF) and histamine, and the ultrastructural effects of PAF in the skin of atopic and normal
subjects. Clin Exp Dermatol 1999; 24: 112-117
Cerio R and Archer CB. eds. Clinical Investigation of Skin Disorders. Publisher: Arnold, 1998; pp 1-58.
Sabroe RA, Kennedy CTC, Archer CB. The effects of topical doxepin on the responses to histamine, substance P
and prostaglandin E2 in human skin. Br J Dermatol 1997; 137: 386-390.
Archer CB and Robertson SJ. Black and White Skin Diseases: An atlas and text. Publisher: Blackwell Science,
1995; pp 1-296.
Williams HC, Burney PGJ, Hay RJ, Archer CB et al. The UK Working Party’s Diagnostic Criteria for Atopic
Dermatitis. 1. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol 1994; 131:
383-396.
1 of 2
Archer CB. Platelet Activating Factor (PAF) - A Mediator of Inflammation in the skin: Medical Implications; Clin
Exp Dermatol 1993; 18: 489-495.
Archer CB, Page CP, Juhlin L, Morley J, MacDonald DM. Delayed onset synergism between leukotriene B4 and
prostaglandin E2 in human skin. Prostaglandins 1987; 33: 799-805.
Archer CB. Cyclic nucleotide metabolism in atopic dermatitis. Clin Exp Dermatol 1987; 12: 424-431
Archer CB, MacDonald DM, Morley J, Page CP, Paul W, Sanjar S. Effects of serum albumin, indomethacin and
histamine H1 antagonists on Paf-acether-induced cutaneous inflammatory responses in the skin of
experimental animals and man. Br J Pharmacol 1985; 85: 109-113.
Archer CB, Frohlich W, Page CP, Paul W, Morley J, MacDonald DM. Synergistic interaction between
prostaglandins and Paf-acether in experimental animals and man. Prostaglandins 1984; 27: 495-501.
Archer CB, Page CP, Paul W, Morley J, MacDonald DM. Inflammatory characteristics of platelet activating factor
(Paf-acether) in human skin. Br J Dermatol 1984; 110: 45-50.
Archer CB, Hanson JM, Morley J, MacDonald DM. Mononuclear leukocyte cyclic adenosine monophosphate
responses in psoriasis are normal. J Invest Dermatol 1984; 82: 316-317.
Archer CB, Morley J, MacDonald DM. Impaired lymphocyte cyclic adenosine monophosphate responses in
atopic eczema. Br J Dermatol 1983; 109: 559-564.
2 of 2